Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma

International Journal of Biological Markers

Volumn 26, Issue 2, 2011, Pages 108-116

  Chen, Li ^a   Shi, Yan ^a   Jiang, Cheng ying ^a   Wei, Li xin ^a   Lv, Ya li ^a   Wang, Yu lan ^a   Dai, Guang hai ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; PDGFR ; PDGFR ; Prognosis; VEGF

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959325993     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8322     Document Type: Article

References (44)

1. Ikai I, Arii S, Ichida T, et al. Report of the 16th followup survey of primary liver cancer. Hepatol Res 2005; 32: 163-72.
2. Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays 2001; 23(6): 494-507.
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29 (6 Suppl 16): 15-8.
4. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-316.
5. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. Vascular endothelial growth factor secretion by tumor infiltrating macrophages essentially supports tumor angiogenesis and IgG immune complexes potentiate the process. Cancer Res 2002; 62: 7042-9.
6. Furuse J. Growth factors as therapeutic targets in HCC. Crit Rev Oncol Hematol 2008; 67: 8-15.
7. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14: 1-14.
8. Clarke ID, Dirks PB. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming. Oncogene 2003; 22: 722-33.
9. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007; 6: 1932-41.
10. Friedman SL. Closing in on the signals of hepatic fibrosis. Gastroenterology 1997; 112: 1406-9.
11. Yuan N, Wang P, Wang X, Wang Z. Expression and significance of platelet derived growth factor and its receptor in liver tissues of patients with liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 2002; 10: 58-60.
12. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO. E-Cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005; 46: 685-93.
13. Lee KH, Min HS, Han SW, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008; 60: 401-7.
14. Shi Y, Chen L, Li J, et al. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in nonsmall cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol 2011; 32: 381-90.
15. Turner BC, Krajewski S, Krajewska M, et al. BAG-1: a novel biomarker predicting long-term survival in earlystage breast cancer. J Clin Oncol 2001; 19: 992-1000.
16. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003; 3: 439-43.
17. Board R, Jayson GC. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat 2005; 8: 75-83.
18. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-312.
19. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 2004; 15: 215-28.
20. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev 2004; 15: 205-13.
21. Davis BH, Rapp UR, Davidson NO. Retinoic acidand transforming growth factor beta differentially inhibit platelet-derived-growth-factor-induced Ito-cell activation. Biochem J 1991; 278: 43-7.
22. Pinzani M, Milani S, Herbst H. Expression of plateletderived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996; 148: 785-800.
23. Jechlinger M, Grunert S, Tamir IH, et al. Expression profiling of epithelial plasticity in tumor progression. Oncogene 2003; 22: 7155-69.
24. Fischer AN, Fuchs E, Mikula M, et al. PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 2007; 26: 3395-405.
25. Maass T, Thieringer FR, Mann A, et al. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer 2011; 128: 1259-68.
26. Mas VR, Maluf DG, Archer KJ, Yanek KC, Fisher RA. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation 2007; 4: 1262-71.
27. Zhao SM, Jiang TL, Li RQ, et al. HCV infection in voluntary donors and its influence on recruitment of donors in Chongqing area. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16: 676-80.
28. Hsing AW, Zhang M, Rashid A, et al. Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. Int J Cancer 2008; 122: 1849-53.
29. Leung N, Chu C, Tam JS. Viral hepatitis C in Hong Kong. Intervirology 2006; 49: 23-7.
30. Ma X, Zhang Q, He X, et al. Trends in prevalence of HIV, syphilis, hepatitis C, hepatitis B, and sexual risk behavior among men who have sex with men. Results of 3 consecutive respondent-driven sampling surveys in Beijing, 2004 through 2006. J Acquir Immune Defic Syndr 2007; 45: 581-7
31. Xiong LS, Cui SF, Zhou JG, Xing Y. Detection and analysis of HAV-HEV, HGV infection in patients with viral hepatitis. Zhonghua Gan Zang Bing Za Zhi 2004; 12: 395-6.
32. Qu JB, Zhang ZW, Shimbo S, et al. Urban-rural comparison of HBV and HCV infection prevalence in eastern China. Biomed Environ Sci 2000; 13: 243-53.
33. Shimbo S, Zhang ZW, Gao WP, et al. Prevalence of hepatitis B and C infection markers among adult women in urban and rural areas in Shaanxi Province, China. Southeast Asian J Trop Med Public Health 1998; 29: 263-8.
34. Yuan JM, Govindarajan S, Henderson BE, Yu MC. Low prevalence of hepatitis C infection in hepatocellular carcinoma (HCC) cases and population controls in Guangxi, a hyperendemic region for HCC in the People's Republic of China. Br J Cancer 1996; 74: 491-3.
35. Shin JE, Jung SA, Kim SE, et al. Expression of MMP- 2, HIF-1alpha and VEGF in colon adenoma and colon cancer. Korean J Gastroenterol 2007; 50: 9-18.
36. Cabuk D, Basaran G, Celikel C, et al. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology 2007; 72: 111-7.
37. Fauconnet S, Bernardini S, Lascombe I, et al. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer. Oncol Rep 2009; 21: 1495-504.
38. Yang ZF, Poon RT. Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken) 2008; 291: 721-34.
39. Jia JB, Zhuang PY, Sun HC, et al. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol 2009; 135: 847-54.
40. Torimura T, Sata M, Ueno T, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998; 29: 986-91.
41. Wang D, Huang HJ, Kazlauskas A, et al. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 1999; 59: 1464-72.
42. Wysocki PJ. Targeted therapy of hepatocellular cancer. Expert Opin Investig Drugs 2010; 19: 265-74.
43. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
44. Huynh H. Tyrosine kinase inhibitors to treat liver cancer. Expert Opin Emerg Drugs 2010; 15: 13-26.